Who
Ashley Hartmann Kline
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Palvella Therapeutics.
In numbers
- Trades disclosed
- 4
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 27 May 2025
- Last trade
- 5 Feb 2026
- Last filed
- 9 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Feb 2026filed 9 Feb 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,517 at $0.00 | filing |
| 5 Feb 2026filed 9 Feb 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,517 at $0.00 | filing |
| 27 May 2025filed 3 Jun 2025 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,436 at $0.00 | filing |
| 27 May 2025filed 3 Jun 2025 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,496 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.